Reviewing Neon Therapeutics Inc. (NTGN)’s and Alpine Immune Sciences Inc. (NASDAQ:ALPN)’s results

This is a contrast between Neon Therapeutics Inc. (NASDAQ:NTGN) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) based on their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neon Therapeutics Inc. 2 -0.02 15.57M -3.01 0.00
Alpine Immune Sciences Inc. 3 0.00 3.94M -2.95 0.00

In table 1 we can see Neon Therapeutics Inc. and Alpine Immune Sciences Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Neon Therapeutics Inc. 873,296,314.99% -76% -68.2%
Alpine Immune Sciences Inc. 136,374,649.54% -78.2% -67.1%

Liquidity

Neon Therapeutics Inc. has a Current Ratio of 7.3 and a Quick Ratio of 7.3. Competitively, Alpine Immune Sciences Inc.’s Current Ratio is 7.3 and has 7.3 Quick Ratio. ‘s better ability to pay short and long-term obligations than .

Analyst Recommendations

The Recommendations and Ratings for Neon Therapeutics Inc. and Alpine Immune Sciences Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Neon Therapeutics Inc. 0 0 1 3.00
Alpine Immune Sciences Inc. 0 0 0 0.00

Neon Therapeutics Inc. has a 1,200.00% upside potential and a consensus price target of $13.

Insider & Institutional Ownership

Institutional investors owned 69.8% of Neon Therapeutics Inc. shares and 46.5% of Alpine Immune Sciences Inc. shares. Insiders owned 3.8% of Neon Therapeutics Inc. shares. On the other hand, insiders owned about 0.1% of Alpine Immune Sciences Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neon Therapeutics Inc. -18.52% -37.69% -53.27% -36.44% -74.73% -43.14%
Alpine Immune Sciences Inc. -6.4% 0.95% -33.7% -36.24% -42.39% 15.22%

For the past year Neon Therapeutics Inc. has -43.14% weaker performance while Alpine Immune Sciences Inc. has 15.22% stronger performance.

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.